Faron Pharmaceuticals Oy (FARN) Price & Analysis

Compare

38 Followers

FARN Stock Chart & Stats

180.00p

-2.73p(-1.37%)

At close: Jan 09 4:00 PM EST

180.00p

-2.73p(-1.37%)

Day’s Range― - ―

52-Week Range140.00p - 270.00p

Previous CloseN/A

Volume750.00

Average Volume (3M)46.62K

Market Cap

£212.88M

Enterprise Value270.38M

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta0.99

Next Earnings

Mar 20, 2026

EPS Estimate

-0.1

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.86

Shares Outstanding113,561,870

10 Day Avg. Volume70,409

30 Day Avg. Volume46,616

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

£1,000.00

Price Target Upside455.56% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Clinical EfficacyUpdated Phase 2 BEXMAB data continue to strengthen, with deeper complete response rates in frontline HR-MDS, underscoring the curative potential of Bexmarilimab in this patient population.

Regulatory SupportThe FDA supports a single seamless Phase 2/3 registrational study to evaluate bexmarilimab in frontline high-risk myelodysplastic syndrome, enabling accelerated approval at interim analysis and full approval on overall survival.

Safety ProfileSafety remains favorable with no new signals and continued evidence of hematologic recovery, positioning Bexmarilimab as one of the most promising late-stage immunotherapies for HR-MDS.

Bears Say

Development RisksThere are risks related to clinical development, competition, the novel Clever-1 mechanism, commercialization, reimbursement, pricing, business development, and capital markets.

Financial PositionFinancially, Faron ended June with €13.5 million in cash and an extended runway into 1Q26 following an oversubscribed €12 million raise and an up to €35 million convertible bond facility.

Faron Pharmaceuticals Oy News

Faron Pharmaceuticals’ Bexmarilimab Shows Promising Results in HR-MDS Treatment

The latest announcement is out from Faron Pharmaceuticals Oy ( ($GB:FARN) ). Faron Pharmaceuticals announced updated data from...

2h ago

Faron Pharmaceuticals Registers New Shares to Enhance Market Position

An announcement from Faron Pharmaceuticals Oy ( ($GB:FARN) ) is now available. Faron Pharmaceuticals Ltd has approved the...

17d ago

Faron Pharmaceuticals Approves New Share Issuance Amid Convertible Bond Strategy

Faron Pharmaceuticals Oy ( ($GB:FARN) ) has shared an announcement. Faron Pharmaceuticals Ltd has approved the exercise of...

17d ago

Faron Pharmaceuticals Announces Option Exercise and Equity Issue

Faron Pharmaceuticals Oy ( ($GB:FARN) ) has provided an announcement. Faron Pharmaceuticals Ltd announced the exercise of options...

1M ago

Faron Pharmaceuticals Oy’s Bexmarilimab Shows Promise in HR-MDS Trials with FDA Support, Reinforcing Buy Rating

Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Faron Pharmaceuticals Oy, retaining the price target...

1M ago

Faron Pharmaceuticals Updates Half-Year Financial Results and Achieves Key Milestones

Faron Pharmaceuticals Oy ( ($GB:FARN) ) just unveiled an announcement. Faron Pharmaceuticals Ltd announced a correction to its...

1M ago

Faron Pharmaceuticals Achieves Key Milestones in H1 2025

The latest announcement is out from Faron Pharmaceuticals Oy ( ($GB:FARN) ). Faron Pharmaceuticals Ltd reported significant clinical...

2M ago

Faron Pharmaceuticals to Announce Half-Year Financial Results

Faron Pharmaceuticals Oy ( ($GB:FARN) ) has issued an announcement. Faron Pharmaceuticals Ltd announced that it will release...

2M ago

Faron Pharmaceuticals Advances Bexmarilimab in HR-MDS Treatment Following FDA Guidance

Faron Pharmaceuticals Oy ( ($GB:FARN) ) has issued an update. Faron Pharmaceuticals Ltd has received positive feedback from...

2M ago

Faron Pharmaceuticals Approves Share Subscription for Bond Amortisation

Faron Pharmaceuticals Oy ( ($GB:FARN) ) has provided an update. Faron Pharmaceuticals Ltd has approved the exercise of...

2M ago

FARN FAQ

What was Faron Pharmaceuticals Oy’s price range in the past 12 months?

Faron Pharmaceuticals Oy lowest share price was 140.00p and its highest was 270.00p in the past 12 months.

What is Faron Pharmaceuticals Oy’s market cap?

Faron Pharmaceuticals Oy’s market cap is £212.88M.

When is Faron Pharmaceuticals Oy’s upcoming earnings report date?

Faron Pharmaceuticals Oy’s upcoming earnings report date is Mar 20, 2026 which is in 151 days.

How were Faron Pharmaceuticals Oy’s earnings last quarter?

Faron Pharmaceuticals Oy released its earnings results on Aug 27, 2025. The company reported -0.862p earnings per share for the quarter, the consensus estimate of -0.862p by 0p.

Is Faron Pharmaceuticals Oy overvalued?

According to Wall Street analysts Faron Pharmaceuticals Oy’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Faron Pharmaceuticals Oy pay dividends?

Faron Pharmaceuticals Oy does not currently pay dividends.

What is Faron Pharmaceuticals Oy’s EPS estimate?

Faron Pharmaceuticals Oy’s EPS estimate is -0.1.

How many shares outstanding does Faron Pharmaceuticals Oy have?

Faron Pharmaceuticals Oy has 113,561,870 shares outstanding.

What happened to Faron Pharmaceuticals Oy’s price movement after its last earnings report?

Faron Pharmaceuticals Oy reported an EPS of -0.862p in its last earnings report, expectations of -0.862p. Following the earnings report the stock price went down -4.494%.

Which hedge fund is a major shareholder of Faron Pharmaceuticals Oy?

Currently, no hedge funds are holding shares in GB:FARN

Company Description

Faron Pharmaceuticals Oy

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company develops a pipeline of immune modulation based proprietary drug candidates for unmet need, including immuno-oncology, and organ protection and regenerative medicine. Its lead product candidates are Traumakine, an intravenous interferon beta-1a therapy for the treatment of acute respiratory distress syndrome, COVID-19, acute kidney injury, cardiac protection, solid organ transplant, and ischemia reperfusion injury; and Bexmarilimab, a novel precision cancer immunotherapy candidate for treating solid tumors, non-small cell lung carcinoma, and hematological malignancies. The company also develops Haematokine, a new chemical entity AOC3 inhibitor for the treatment of hematological malignancies and bone marrow. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.

Faron Pharmaceuticals Oy (FARN) Earnings & Revenues

Historic Earnings Reports

FARN Stock 12 Month Forecast

Average Price Target

1,000.00p

▲(455.56% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"164":"164p","1001":"1,001p","373.25":"373.3p","582.5":"582.5p","791.75":"791.8p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1000,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">1.00K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1000,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">1.00K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1000,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">1.00K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[164,373.25,582.5,791.75,1001],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,205,266.15384615384613,327.3076923076923,388.46153846153845,449.61538461538464,510.7692307692308,571.9230769230769,633.0769230769231,694.2307692307693,755.3846153846154,816.5384615384615,877.6923076923077,938.8461538461538,{"y":1000,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,205,266.15384615384613,327.3076923076923,388.46153846153845,449.61538461538464,510.7692307692308,571.9230769230769,633.0769230769231,694.2307692307693,755.3846153846154,816.5384615384615,877.6923076923077,938.8461538461538,{"y":1000,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,205,266.15384615384613,327.3076923076923,388.46153846153845,449.61538461538464,510.7692307692308,571.9230769230769,633.0769230769231,694.2307692307693,755.3846153846154,816.5384615384615,877.6923076923077,938.8461538461538,{"y":1000,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":215,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":228,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":165,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":180,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":205,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":172.5,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":170,"date":1740787200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":209,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":192.5,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":252.5,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":202.5,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":192.5,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":205,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >